Abstract CN42
Background
Maintenance therapies (Bevacizumab and PARP inhibitors) as standard of care for ovarian cancer increases patient visits and time spent in hospital face to face (F2F) clinics. In 2019, we launched a pilot pharmacist and nurse-led (PN) telephone clinic (with consultant supervision) to address the workload. A patient and staff survey was conducted after 6 months to assess the efficiency and satisfaction of the PN telephone clinic.
Methods
All patients included had received either a PARP inhibitor or Bevacizumab during the allotted time period (Aug2019-Feb2020). An anonymised survey was provided to all patients booked into the PN telephone clinic and a second survey was sent to all relevant staff within the team. The surveys were designed to explore patient experience (12 questions including waiting time, confidence in the nurse/pharmacist consultation) and staff satisfaction. Patient demographic and treatment details were obtained from electronic records.
Results
69% (25/36) of all patients prescribed maintenance Bevacizumab or a PARP inhibitor (92% maintenance, 8% treatment) had a PN telephone clinic consultation (median age 62 (38-86)). 31% (11/36) remained in F2F clinics. 8% (2/25) of those in PN telephone clinic reverted back to F2F clinic due to complex toxicity management. 83% (19/23) of the patient surveys were returned (1 excluded in analysis as incomplete). 100% reported no waiting time; 100% felt very confident/confident in the nurse/pharmacist consultation; 100% felt very confident/ confident managing side effects and 100% felt involved in making their care decisions. Of 77% (10/13) staff surveys returned, 100% felt the PN telephone clinic had helped in the management of F2F clinics. Further survey finding details will be presented.
Conclusions
A nurse and pharmacist-led telephone clinic service can be an effective and efficient way of managing patients on maintenance therapies. The patient survey indicates that overall patient satisfaction was high. Following this pilot, this new model of care is now a permanent, established part of the gynaecological medical oncology service.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
P. Jupp: Honoraria (self): Astrazeneca; Travel/Accommodation/Expenses: Tesaro; Honoraria (self): Clovis. L. Appadu: Honoraria (self), Travel/Accommodation/Expenses: Tesaro. S. Banerjee: Honoraria (self), Research grant/Funding (institution): Astrazeneca; Honoraria (self): Amgen; Honoraria (self): Clovis; Honoraria (self), Research grant/Funding (institution): GSK; Honoraria (self): Roche; Honoraria (self): GenMab; Honoraria (self): Seattle Genetics; Research grant/Funding (institution): Carrick. All other authors have declared no conflicts of interest.